Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
15.01. | Regeneron shares positive phase 3 results for Libtayo in high-risk skin cancer | ||
14.01. | J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition | ||
14.01. | Eli Lilly to acquire Scorpion's solid tumour programme in deal worth $2.5bn | ||
14.01. | Boehringer gains access to Synaffix's ADC technology through $1.3bn licensing deal | ||
13.01. | Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn | ||
13.01. | GSK to expand gastrointestinal cancer pipeline with $1bn IDRx acquisition | ||
13.01. | Sanofi announces positive phase 3 results for subcutaneous Sarclisa in multiple myeloma | ||
10.01. | Bayer's non-hormonal menopause drug shows promise in phase 3 breast cancer trial | ||
10.01. | Pfizer shares positive late-stage results for sasanlimab combination in bladder cancer | ||
10.01. | Eli Lilly and Alchemab Therapeutics partner to develop new ALS therapies | ||
09.01. | AstraZeneca/Merck's Lynparza recommended by NICE to treat advanced breast cancer | ||
09.01. | Sanofi and Alloy Therapeutics enter central nervous system deal worth over $427m | ||
09.01. | FDA accepts updated protocol for Annovis' phase 3 Alzheimer's disease study | ||
08.01. | Bristol Myers Squibb shares positive phase 3 results for Sotyktu in psoriatic arthritis | ||
08.01. | MHRA approves Italfarmaco's Duvyzat to treat Duchenne muscular dystrophy | ||
08.01. | Axsome announces positive results from phase 3 Alzheimer's disease programme | ||
07.01. | Sanofi and SK bioscience expand pneumococcal vaccine collaboration | ||
07.01. | Prostate cancer blood test with 'unprecedented accuracy' cuts biopsies by 50% | ||
07.01. | Publicis Health appoints Annabelle Sandeman as chief growth officer in UK | ||
06.01. | Roche gains rights to Innovent's ADC candidate in deal worth over $1bn | ||
06.01. | Bristol Myers Squibb's injectable Opdivo formulation granted FDA approval | ||
06.01. | J&J expands atopic dermatitis pipeline with Kaken Pharmaceutical licensing deal | ||
03.01. | Amgen's Imdyllytra approved by MHRA to treat small cell lung cancer in adults | ||
03.01. | BeiGene's Tevimbra combination granted FDA approval to treat gastric cancer | ||
03.01. | Novartis' investigational spinal muscular atrophy gene therapy shows promise in late-stage study |